AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Receives Average Rating of “Hold” from Brokerages

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have received an average rating of “Hold” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $8.34.

Several equities research analysts recently weighed in on AMAG shares. Barclays restated a “buy” rating and issued a $11.00 target price on shares of AMAG Pharmaceuticals in a report on Sunday, March 8th. SVB Leerink decreased their price objective on shares of AMAG Pharmaceuticals from $11.00 to $9.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating and set a $8.75 target price on the stock in a report on Wednesday, May 6th. Needham & Company LLC restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, March 9th. Finally, BidaskClub raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday.

Shares of AMAG Pharmaceuticals stock traded down $0.54 during midday trading on Friday, reaching $7.28. 822,444 shares of the company’s stock traded hands, compared to its average volume of 631,545. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.54. AMAG Pharmaceuticals has a 52 week low of $4.41 and a 52 week high of $13.53. The company’s 50 day simple moving average is $7.85 and its 200 day simple moving average is $8.75. The company has a market cap of $268.01 million, a price-to-earnings ratio of -0.72 and a beta of 0.94.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Monday, May 11th. The specialty pharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.27). AMAG Pharmaceuticals had a negative return on equity of 28.28% and a negative net margin of 115.05%. The business had revenue of $68.66 million for the quarter, compared to analyst estimates of $64.95 million. As a group, equities research analysts predict that AMAG Pharmaceuticals will post -1.36 earnings per share for the current year.

Several large investors have recently bought and sold shares of AMAG. Ironwood Investment Management LLC lifted its position in shares of AMAG Pharmaceuticals by 6.7% in the 1st quarter. Ironwood Investment Management LLC now owns 31,781 shares of the specialty pharmaceutical company’s stock worth $196,000 after acquiring an additional 2,001 shares during the period. UBS Asset Management Americas Inc. lifted its position in AMAG Pharmaceuticals by 5.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 43,146 shares of the specialty pharmaceutical company’s stock worth $525,000 after purchasing an additional 2,084 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in AMAG Pharmaceuticals by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 205,514 shares of the specialty pharmaceutical company’s stock worth $2,502,000 after buying an additional 4,319 shares in the last quarter. Royal Bank of Canada increased its holdings in AMAG Pharmaceuticals by 24.7% in the 1st quarter. Royal Bank of Canada now owns 26,887 shares of the specialty pharmaceutical company’s stock valued at $166,000 after buying an additional 5,318 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of AMAG Pharmaceuticals by 4.6% in the 4th quarter. Rhumbline Advisers now owns 120,189 shares of the specialty pharmaceutical company’s stock valued at $1,463,000 after buying an additional 5,339 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Story: S&P/TSX Index

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.